{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:44:05Z","timestamp":1774442645955,"version":"3.50.1"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00210-025-04169-w","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T02:23:14Z","timestamp":1745374994000},"page":"13153-13172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Polymeric and lipidic nanoparticles in transforming anti-HIV combinational therapy: can they turn the tide?"],"prefix":"10.1007","volume":"398","author":[{"given":"Pankaj","family":"Popli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Teja","family":"Meduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teenu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranadheer Reddy","family":"Challa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhaskar","family":"Vallamkonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phanikumar Reddy","family":"Satti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Swami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"issue":"3","key":"4169_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11051-023-05690-w","volume":"25","author":"R Abbasi","year":"2023","unstructured":"Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L (2023) Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J Nanopart Res 25(3):43. https:\/\/doi.org\/10.1007\/s11051-023-05690-w","journal-title":"J Nanopart Res"},{"issue":"7","key":"4169_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3390\/ph14070645","volume":"14","author":"SA Abd-Algaleel","year":"2021","unstructured":"Abd-Algaleel SA, Abdel-Bar HM, Metwally AA, Hathout RM (2021) Evolution of the computational pharmaceutics approaches in the modeling and prediction of drug payload in lipid and polymeric nanocarriers. Pharmaceuticals 14(7):645. https:\/\/doi.org\/10.3390\/ph14070645","journal-title":"Pharmaceuticals"},{"key":"4169_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43094-021-00233-3","volume":"7","author":"VS Adhao","year":"2021","unstructured":"Adhao VS, Chaudhari SR, Ambhore JP, Sangolkar S, Thenge RR, Cheke RS et al (2021) Reverse phase-liquid chromatography assisted protocol for simultaneous determination of lamivudine and tenofovir disoproxil fumarate in combined medication used to control HIV infection: an investigative approach. Future J Pharm Sci 7:1\u201311. https:\/\/doi.org\/10.1186\/s43094-021-00233-3","journal-title":"Future J Pharm Sci"},{"issue":"17","key":"4169_CR4","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1039\/C5NR01285F","volume":"7","author":"RR Adhikary","year":"2015","unstructured":"Adhikary RR, More P, Banerjee R (2015) Smart nanoparticles as targeting platforms for HIV infections. Nanoscale 7(17):7520\u20137534. https:\/\/doi.org\/10.1039\/C5NR01285F","journal-title":"Nanoscale"},{"key":"4169_CR5","doi-asserted-by":"publisher","first-page":"104885","DOI":"10.1016\/j.yrtph.2021.104885","volume":"122","author":"J Allan","year":"2021","unstructured":"Allan J, Belz S, Hoeveler A, Hugas M, Okuda H, Patri A et al (2021) Regulatory landscape of nanotechnology and nanoplastics from a global perspective. Regul Toxicol Pharmacol 122:104885. https:\/\/doi.org\/10.1016\/j.yrtph.2021.104885","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"4169_CR6","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","volume":"8","author":"J Ambrosioni","year":"2021","unstructured":"Ambrosioni J, Petit E, Liegeon G, Laguno M, Mir\u00f3 JM (2021) Primary HIV-1 infection in users of pre-exposure prophylaxis. The Lancet HIV 8(3):e166\u2013e174. https:\/\/doi.org\/10.1016\/S2352-3018(20)30271-X","journal-title":"The Lancet HIV"},{"issue":"3","key":"4169_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/nnm-2022-0248","volume":"18","author":"FD Asl","year":"2023","unstructured":"Asl FD, Mousazadeh M, Taji S, Bahmani A, Khashayar P, Azimzadeh M et al (2023) Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles. Nanomedicine 18(3):279\u2013302. https:\/\/doi.org\/10.2217\/nnm-2022-0248","journal-title":"Nanomedicine"},{"key":"4169_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.actbio.2018.04.045","volume":"74","author":"R Augustine","year":"2018","unstructured":"Augustine R, Ashkenazi DL, Arzi RS, Zlobin V, Shofti R, Sosnik A (2018) Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir\/ritonavir antiretroviral combination. Acta Biomater 74:344\u2013359. https:\/\/doi.org\/10.1016\/j.actbio.2018.04.045","journal-title":"Acta Biomater"},{"issue":"38","key":"4169_CR9","doi-asserted-by":"publisher","first-page":"12586","DOI":"10.1002\/chem.201302097","volume":"J19","author":"MS Aw","year":"2013","unstructured":"Aw MS, Kurian M, Losic D (2013) Polymeric micelles for multidrug delivery and combination therapy. Chem Eur J19(38):12586\u201312601. https:\/\/doi.org\/10.1002\/chem.201302097","journal-title":"Chem Eur"},{"issue":"19","key":"4169_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.31782\/IJCRR.2020.121910","volume":"12","author":"M Baghel","year":"2020","unstructured":"Baghel M, Sailaja I, Shaker IA (2020) Nanotechnology: a curative approach to combat. Int J Cur Res Rev 12(19):149. https:\/\/doi.org\/10.31782\/IJCRR.2020.121910","journal-title":"Int J Cur Res Rev"},{"issue":"11","key":"4169_CR11","doi-asserted-by":"publisher","first-page":"e49792","DOI":"10.1371\/journal.pone.0049792","volume":"7","author":"C Ball","year":"2012","unstructured":"Ball C, Krogstad E, Chaowanachan T, Woodrow KA (2012) Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS ONE 7(11):e49792. https:\/\/doi.org\/10.1371\/journal.pone.0049792","journal-title":"PLoS ONE"},{"key":"4169_CR12","doi-asserted-by":"publisher","first-page":"125166","DOI":"10.1016\/j.ijpharm.2025.125166","volume":"670","author":"A Bazargani","year":"2025","unstructured":"Bazargani A, Hejazi M, Fernandez M, Cordeiro A, Ebode JT, Lewinski N et al (2025) PEGylated solid lipid nanoparticles for the intranasal delivery of combination antiretroviral therapy composed of Atazanavir and Elvitegravir to treat NeuroAIDS. Int J Pharm 670:125166. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125166","journal-title":"Int J Pharm"},{"issue":"5","key":"4169_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/acsptsci.2c00033","volume":"5","author":"S Bhattacharjee","year":"2022","unstructured":"Bhattacharjee S (2022) Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity. ACS Pharmacol Transl Sci 5(5):278\u2013298. https:\/\/doi.org\/10.1021\/acsptsci.2c00033","journal-title":"ACS Pharmacol Transl Sci"},{"key":"4169_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejpb.2018.06.002","volume":"138","author":"S Cao","year":"2019","unstructured":"Cao S, Woodrow KA (2019) Nanotechnology approaches to eradicating HIV reservoirs. Eur J Pharm Biopharm 138:48\u201363. https:\/\/doi.org\/10.1016\/j.ejpb.2018.06.002","journal-title":"Eur J Pharm Biopharm"},{"key":"4169_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M (2016) Current status and prospects of HIV treatment. Curr Opin Virol 18:50\u201356. https:\/\/doi.org\/10.1016\/j.coviro.2016.03.004","journal-title":"Curr Opin Virol"},{"key":"4169_CR16","first-page":"741","volume":"23","author":"C Coughlin","year":"2021","unstructured":"Coughlin C (2021) FDA\u2019s accelerated approval, emergency use authorization, and pre-approval access: considerations for use in public health emergencies and beyond. NCJL Tech 23:741","journal-title":"NCJL Tech"},{"issue":"2","key":"4169_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","volume":"323","author":"JJ Darrow","year":"2020","unstructured":"Darrow JJ, Avorn J, Kesselheim AS (2020) FDA approval and regulation of pharmaceuticals, 1983\u20132018. JAMA 323(2):164\u2013176. https:\/\/doi.org\/10.1001\/jama.2019.20288","journal-title":"JAMA"},{"issue":"1","key":"4169_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2015.35","volume":"1","author":"SG Deeks","year":"2015","unstructured":"Deeks SG, Overbaugh J, Phillips A, Buchbinder S (2015) HIV Infection. Nat Rev Dis Primers 1(1):1\u201322. https:\/\/doi.org\/10.1038\/nrdp.2015.35","journal-title":"Nat Rev Dis Primers"},{"key":"4169_CR19","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jde.2022.11.009","volume":"344","author":"D Denu","year":"2023","unstructured":"Denu D, Ngoma S, Salako RB (2023) Dynamics of solutions of a diffusive time-delayed HIV\/AIDS epidemic model: traveling wave solutions and spreading speeds. J Differ Equ 344:846\u2013890. https:\/\/doi.org\/10.1016\/j.jde.2022.11.009","journal-title":"J Differ Equ"},{"issue":"2","key":"4169_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"J14","author":"N Desai","year":"2012","unstructured":"Desai N (2012) Challenges in development of nanoparticle-based therapeutics. AAPS J14(2):282\u2013295. https:\/\/doi.org\/10.1208\/s12248-012-9339-4","journal-title":"AAPS"},{"issue":"3","key":"4169_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0934-8840(11)80121-0","volume":"282","author":"A D\u00e9sormeaux","year":"1995","unstructured":"D\u00e9sormeaux A, Bergeron MG (1995) Targeting HIV with liposome-encapsulated antivirals. Int J Med Microbiol 282(3):225\u2013231. https:\/\/doi.org\/10.1016\/S0934-8840(11)80121-0","journal-title":"Int J Med Microbiol"},{"issue":"1","key":"4169_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-9-198","volume":"9","author":"CJ Destache","year":"2009","unstructured":"Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A (2009) Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis 9(1):1\u20138. https:\/\/doi.org\/10.1186\/1471-2334-9-198","journal-title":"BMC Infect Dis"},{"issue":"10","key":"4169_CR23","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1093\/jac\/dkq318","volume":"65","author":"CJ Destache","year":"2010","unstructured":"Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA (2010) Antiretroviral release from poly (DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother 65(10):2183\u20132187. https:\/\/doi.org\/10.1093\/jac\/dkq318","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"4169_CR24","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jps.24046","volume":"103","author":"J Duan","year":"2014","unstructured":"Duan J, Freeling JP, Koehn J, Shu C, Ho RJ (2014) Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J Pharm Sci 103(8):2520\u20132529. https:\/\/doi.org\/10.1002\/jps.24046","journal-title":"J Pharm Sci"},{"key":"4169_CR25","doi-asserted-by":"publisher","first-page":"119794","DOI":"10.1016\/j.ijpharm.2020.119794","volume":"588","author":"H Elkateb","year":"2020","unstructured":"Elkateb H, Tatham LM, Cauldbeck H, Niezabitowska E, Owen A, Rannard S et al (2020) Optimization of the synthetic parameters of lipid polymer hybrid nanoparticles dual loaded with darunavir and ritonavir for the treatment of HIV. Int J Pharm 588:119794. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119794","journal-title":"Int J Pharm"},{"key":"4169_CR26","doi-asserted-by":"publisher","first-page":"100087","DOI":"10.1016\/j.jciso.2023.100087","volume":"11","author":"H Elkateb","year":"2023","unstructured":"Elkateb H, Cauldbeck H, Niezabitowska E, Hogarth C, Arnold K, Rannard S et al (2023) High drug loading solid lipid nanoparticles, nanostructured lipid carriers and nanoemulsions for the dual drug delivery of the HIV drugs darunavir and ritonavir. JCIS Open 11:100087. https:\/\/doi.org\/10.1016\/j.jciso.2023.100087","journal-title":"JCIS Open"},{"issue":"3","key":"4169_CR27","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1113244","volume":"367","author":"J Esbj\u00f6rnsson","year":"2012","unstructured":"Esbj\u00f6rnsson J, M\u00e5nsson F, Kvist A, Isberg P-E, Nowroozalizadeh S, Biague AJ et al (2012) Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med 367(3):224\u2013232. https:\/\/doi.org\/10.1056\/NEJMoa1113244","journal-title":"N Engl J Med"},{"issue":"2","key":"4169_CR28","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1021\/acsami.1c17415","volume":"14","author":"B Eshaghi","year":"2022","unstructured":"Eshaghi B, Fofana J, Nodder SB, Gummuluru S, B.r.M. Reinhard, (2022) Virus-mimicking polymer nanoparticles targeting CD169+ macrophages as long-acting nanocarriers for combination antiretrovirals. ACS Appl Mater Interfaces 14(2):2488\u20132500. https:\/\/doi.org\/10.1021\/acsami.1c17415","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"4169_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/metabo15030201","volume":"15","author":"S Fan","year":"2025","unstructured":"Fan S, Wang W, Che W, Xu Y, Jin C, Dong L et al (2025) Nanomedicines targeting metabolic pathways in the tumor microenvironment: future perspectives and the role of AI. Metabolites [internet] 15(3):201","journal-title":"Metabolites [internet]"},{"key":"4169_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4415\/Ann_10_01_02","volume":"46","author":"E Fanales-Belasio","year":"2010","unstructured":"Fanales-Belasio E, Raimondo M, Suligoi B, Butt\u00f2 S (2010) HIV virology and pathogenetic mechanisms of infection: a brief overview. Annali Dell\u2019istituto Superiore di Sanita 46:5\u201314. https:\/\/doi.org\/10.4415\/Ann_10_01_02","journal-title":"Annali Dell'istituto Superiore di Sanita"},{"issue":"2","key":"4169_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.virol.2011.07.004","volume":"417","author":"G F\u00e9rir","year":"2011","unstructured":"F\u00e9rir G, Palmer KE, Schols D (2011) Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417(2):253\u2013258. https:\/\/doi.org\/10.1016\/j.virol.2011.07.004","journal-title":"Virology"},{"issue":"2","key":"4169_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1021\/acsinfecdis.9b00285","volume":"6","author":"TN Figueira","year":"2020","unstructured":"Figueira TN, Domingues MM, Illien F, Cadima-Couto I, Todorovski T, Andreu D et al (2020) Enfuvirtide-protoporphyrin IX dual-loaded liposomes: in vitro evidence of synergy against HIV-1 entry into cells. ACS Infect Dis 6(2):224\u2013236. https:\/\/doi.org\/10.1021\/acsinfecdis.9b00285","journal-title":"ACS Infect Dis"},{"issue":"17","key":"4169_CR33","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1039\/D0BM00558D","volume":"8","author":"R Foulkes","year":"2020","unstructured":"Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C (2020) The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci 8(17):4653\u20134664. https:\/\/doi.org\/10.1039\/D0BM00558D","journal-title":"Biomater Sci"},{"issue":"6","key":"4169_CR34","doi-asserted-by":"publisher","first-page":"e3000328","DOI":"10.1371\/journal.pbio.3000328","volume":"17","author":"JR Francica","year":"2019","unstructured":"Francica JR, Laga R, Lynn GM, Mu\u017e\u00edkov\u00e1 G, Androvi\u010d L, Aussedat B et al (2019) Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. PLOS Biol 17(6):e3000328. https:\/\/doi.org\/10.1371\/journal.pbio.3000328","journal-title":"PLOS Biol"},{"issue":"1","key":"4169_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/aid.2014.0210","volume":"31","author":"JP Freeling","year":"2015","unstructured":"Freeling JP, Koehn J, Shu C, Sun J, Ho RJ (2015) Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retroviruses 31(1):107\u2013114. https:\/\/doi.org\/10.1089\/aid.2014.0210","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4169_CR36","doi-asserted-by":"publisher","unstructured":"Ghosh M, Kumar R (2024) Regulatory issues in nanotechnology. Nanotechnology theranostics in livestock diseases and management: Springer, p 765\u201388. https:\/\/doi.org\/10.1007\/978-981-16-1610-5_31","DOI":"10.1007\/978-981-16-1610-5_31"},{"issue":"1","key":"4169_CR37","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1038\/s41598-018-26313-8","volume":"8","author":"L Girard","year":"2018","unstructured":"Girard L, Birse K, Holm JB, Gajer P, Humphrys MS, Garber D et al (2018) Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates. Sci Rep 8(1):8059. https:\/\/doi.org\/10.1038\/s41598-018-26313-8","journal-title":"Sci Rep"},{"issue":"2","key":"4169_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2174\/2468187308666180430123942","volume":"8","author":"TK Grewal","year":"2018","unstructured":"Grewal TK, Majeed S, Sharma S (2018) Synthesis and characterization of Poly-(lactide-co-glycolide) nanoparticles encapsulating zidovudine, didanosine and ritonavir. Curr Nanomed (Formerly: Recent Patents on Nanomedicine) 8(2):135\u2013146. https:\/\/doi.org\/10.2174\/2468187308666180430123942","journal-title":"Curr Nanomed (Formerly: Recent Patents on Nanomedicine)"},{"issue":"12","key":"4169_CR39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1080\/17512433.2018.1549484","volume":"11","author":"G Guaraldi","year":"2018","unstructured":"Guaraldi G, Pintassilgo I, Milic J, Mussini C (2018) Managing antiretroviral therapy in the elderly HIV patient. Expert Rev Clin Pharmacol 11(12):1171\u20131181. https:\/\/doi.org\/10.1080\/17512433.2018.1549484","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"4169_CR40","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3390\/nano13040770","volume":"13","author":"MD Guedes","year":"2023","unstructured":"Guedes MD, Marques MS, Berlitz SJ, Facure MH, Correa DS, Steffens C et al (2023) Lamivudine and zidovudine-loaded nanostructures: green chemistry preparation for pediatric oral administration. Nanomaterials 13(4):770. https:\/\/doi.org\/10.3390\/nano13040770","journal-title":"Nanomaterials"},{"issue":"5","key":"4169_CR41","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejps.2012.02.003","volume":"46","author":"PN Gupta","year":"2012","unstructured":"Gupta PN, Pattani A, Curran RM, Kett VL, Andrews GP, Morrow RJ et al (2012) Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. Eur J Pharm Sci 46(5):315\u2013322. https:\/\/doi.org\/10.1016\/j.ejps.2012.02.003","journal-title":"Eur J Pharm Sci"},{"key":"4169_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11095-008-9765-2","volume":"26","author":"AS Ham","year":"2009","unstructured":"Ham AS, Cost MR, Sassi AB, Dezzutti CS, Rohan LC (2009) Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 26:502\u2013511. https:\/\/doi.org\/10.1007\/s11095-008-9765-2","journal-title":"Pharm Res"},{"key":"4169_CR43","doi-asserted-by":"publisher","unstructured":"Han X, Li Y, Liu W, Chen X, Song Z, Wang X, Jiang Z\u00a0(2020) The applications of magnetic particle imaging: from cell to\u00a0body. Diagnostics 10(10). https:\/\/doi.org\/10.3390\/diagnostics10100800","DOI":"10.3390\/diagnostics10100800"},{"key":"4169_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.envint.2017.03.001","volume":"102","author":"X Hu","year":"2017","unstructured":"Hu X, Sun A, Kang W, Zhou Q (2017) Strategies and knowledge gaps for improving nanomaterial biocompatibility. Environ Int 102:177\u2013189. https:\/\/doi.org\/10.1016\/j.envint.2017.03.001","journal-title":"Environ Int"},{"issue":"5","key":"4169_CR45","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nmat3014","volume":"10","author":"DJ Irvine","year":"2011","unstructured":"Irvine DJ (2011) One nanoparticle, one kill. Nat Mater 10(5):342\u2013343. https:\/\/doi.org\/10.1038\/nmat3014","journal-title":"Nat Mater"},{"issue":"12","key":"4169_CR46","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1021\/acs.molpharmaceut.5b00544","volume":"12","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Cao S, Bright DK, Bever AM, Blakney AK, Suydam IT et al (2015) Nanoparticle-based ARV drug combinations for synergistic inhibition of cell-free and cell\u2013cell HIV transmission. Mol Pharm 12(12):4363\u20134374. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00544","journal-title":"Mol Pharm"},{"key":"4169_CR47","unstructured":"Johnson&Johnson (2020) Janssen announces health canada approval of CABENUVA\u2122, the first long-acting regimen for the treatment of HIV 2020. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/janssen-announces-health-canada-approval-of-cabenuva-the-first-long-acting-regimen-for-the-treatment-of-hiv. Accessed 16 Apr 2025"},{"key":"4169_CR48","doi-asserted-by":"publisher","unstructured":"Johansson E, Nazziwa J, Freyhult E, Hong M-G, Neptin M, Karlson S et al (2024) Distinct plasma protein profiles distinguish faster from slower disease progression in HIV-1 and HIV-2 infections. medRxiv:2024.07. 23.24310457. https:\/\/doi.org\/10.1101\/2024.07.23.24310457","DOI":"10.1101\/2024.07.23.24310457"},{"key":"4169_CR49","doi-asserted-by":"publisher","unstructured":"Kanki PJ, Koofhethile CK (2023) HIV\/AIDS global epidemic. Infectious Diseases: Springer, pp 221\u201350. https:\/\/doi.org\/10.1007\/978-1-0716-2463-0_522","DOI":"10.1007\/978-1-0716-2463-0_522"},{"issue":"6","key":"4169_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/joim.12280","volume":"276","author":"R Kannan","year":"2014","unstructured":"Kannan R, Nance E, Kannan S, Tomalia DA (2014) Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications. J Intern Med 276(6):579\u2013617. https:\/\/doi.org\/10.1111\/joim.12280","journal-title":"J Intern Med"},{"key":"4169_CR51","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.2147\/IJN.S109943","volume":"11","author":"A Kaushik","year":"2016","unstructured":"Kaushik A, Jayant RD, Nair M (2016) Advancements in nano-enabled therapeutics for neuroHIV management. Int J Nanomed 11:4317\u20134325. https:\/\/doi.org\/10.2147\/IJN.S109943","journal-title":"Int J Nanomed"},{"issue":"3","key":"4169_CR52","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/app12031468","volume":"12","author":"V Kenchappa","year":"2022","unstructured":"Kenchappa V, Cao R, Venketaraman V, Betageri GV (2022) Liposomes as carriers for the delivery of efavirenz in combination with glutathione-an approach to combat opportunistic infections. Appl Sci (Basel) 12(3):1468. https:\/\/doi.org\/10.3390\/app12031468","journal-title":"Appl Sci (Basel)"},{"issue":"1","key":"4169_CR53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1517\/17425247.2011.543673","volume":"8","author":"NM Khalil","year":"2011","unstructured":"Khalil NM, Carraro E, C\u00f3tica LF, Mainardes RM (2011) Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin Drug Deliv 8(1):95\u2013112. https:\/\/doi.org\/10.1517\/17425247.2011.543673","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"4169_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/wnan.118","volume":"2","author":"PS Kim","year":"2010","unstructured":"Kim PS, Read SW (2010) Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(6):693\u2013702. https:\/\/doi.org\/10.1002\/wnan.118","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"11","key":"4169_CR55","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1089\/aid.2012.0277","volume":"28","author":"PF Kiser","year":"2012","unstructured":"Kiser PF, Mesquita PM, Herold BC (2012) A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses 28(11):1373\u20131378. https:\/\/doi.org\/10.1089\/aid.2012.0277","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4169_CR56","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","volume":"21","author":"FM Koechlin","year":"2017","unstructured":"Koechlin FM, Fonner VA, Dalglish SL, O\u2019Reilly KR, Baggaley R, Grant RM et al (2017) Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav 21:1325\u20131335. https:\/\/doi.org\/10.1007\/s10461-016-1627-z","journal-title":"AIDS Behav"},{"issue":"7458","key":"4169_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/499291a","volume":"499","author":"NL Komarova","year":"2013","unstructured":"Komarova NL, Boland CR (2013) Calculated treatment. Nature 499(7458):291\u2013292. https:\/\/doi.org\/10.1038\/499291a","journal-title":"Nature"},{"key":"4169_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","volume":"275","author":"JC Kraft","year":"2018","unstructured":"Kraft JC, McConnachie LA, Koehn J, Kinman L, Sun J, Collier AC et al (2018) Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation. J Control Release 275:229\u2013241. https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.003","journal-title":"J Control Release"},{"issue":"2","key":"4169_CR59","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/21691401.2014.883400","volume":"43","author":"L Kumar","year":"2015","unstructured":"Kumar L, Verma S, Prasad DN, Bhardwaj A, Vaidya B, Jain AK (2015) Nanotechnology: a magic bullet for HIV AIDS treatment. Artif Cells Nanomed Biotechnol 43(2):71\u201386. https:\/\/doi.org\/10.3109\/21691401.2014.883400","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"1\u20132","key":"4169_CR60","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ijpharm.2007.03.012","volume":"340","author":"Y-C Kuo","year":"2007","unstructured":"Kuo Y-C, Su F-L (2007) Transport of stavudine, delavirdine, and saquinavir across the blood\u2013brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 340(1\u20132):143\u2013152. https:\/\/doi.org\/10.1016\/j.ijpharm.2007.03.012","journal-title":"Int J Pharm"},{"issue":"12","key":"4169_CR61","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1021\/acs.molpharmaceut.9b00855","volume":"16","author":"G Lee","year":"2019","unstructured":"Lee G, Han S, Inocencio I, Cao E, Hong J, Phillips AR et al (2019) Lymphatic uptake of liposomes after intraperitoneal administration primarily occurs via the diaphragmatic lymphatics and is dependent on liposome surface properties. Mol Pharm 16(12):4987\u20134999. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00855","journal-title":"Mol Pharm"},{"issue":"1","key":"4169_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/17425247.2017.1360863","volume":"15","author":"D Lembo","year":"2018","unstructured":"Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R (2018) Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opin Drug Deliv 15(1):93\u2013114. https:\/\/doi.org\/10.1080\/17425247.2017.1360863","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"4169_CR63","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/QAD.0000000000000971","volume":"30","author":"W Li","year":"2016","unstructured":"Li W, Yu F, Wang Q, Qi Q, Su S, Xie L et al (2016) Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. AIDS 30(6):827\u2013838. https:\/\/doi.org\/10.1097\/QAD.0000000000000971","journal-title":"AIDS"},{"issue":"1","key":"4169_CR64","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/10717544.2018.1455763","volume":"25","author":"W Li","year":"2018","unstructured":"Li W, Junyong W, Jiang Z, Jingjing W, Daxiong X, Shilin L et al (2018) Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile. Drug Deliv 25(1):827\u2013837. https:\/\/doi.org\/10.1080\/10717544.2018.1455763","journal-title":"Drug Deliv"},{"issue":"11","key":"4169_CR65","doi-asserted-by":"publisher","first-page":"2106456","DOI":"10.1002\/adma.202106456","volume":"34","author":"J Li","year":"2022","unstructured":"Li J, Chen C, Xia T (2022) Understanding nanomaterial\u2013liver interactions to facilitate the development of safer nanoapplications. Adv Mater 34(11):2106456. https:\/\/doi.org\/10.1002\/adma.202106456","journal-title":"Adv Mater"},{"issue":"5","key":"4169_CR66","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1208\/s12249-021-01981-4","volume":"22","author":"K Mahajan","year":"2021","unstructured":"Mahajan K, Rojekar S, Desai D, Kulkarni S, Bapat G, Zinjarde S et al (2021) Layer-by-layer assembled nanostructured lipid carriers for CD-44 receptor\u2013based targeting in HIV-infected macrophages for efficient HIV-1 inhibition. AAPS PharmSciTech 22(5):171. https:\/\/doi.org\/10.1208\/s12249-021-01981-4","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"4169_CR67","doi-asserted-by":"publisher","first-page":"3810175","DOI":"10.1155\/2016\/3810175","volume":"2016","author":"F Makita-Chingombe","year":"2016","unstructured":"Makita-Chingombe F, Kutscher HL, DiTursi SL, Morse GD, Maponga CC (2016) Poly (lactic-co-glycolic) acid-chitosan dual loaded nanoparticles for antiretroviral nanoformulations. J Drug Deliv 2016(1):3810175. https:\/\/doi.org\/10.1155\/2016\/3810175","journal-title":"J Drug Deliv"},{"key":"4169_CR68","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/IJN.S7681","volume":"5","author":"R Mallipeddi","year":"2010","unstructured":"Mallipeddi R, Rohan LC (2010) Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed 5:533\u2013547. https:\/\/doi.org\/10.2147\/IJN.S7681","journal-title":"Int J Nanomed"},{"key":"4169_CR69","unstructured":"Malta R, Neves JD, Sarmento B, Machado R, L\u00facio M, Viseu T (2017) Co-delivery of two anti-HIV drug nanocrystals from electrospun nanofibers. https:\/\/repositorium.sdum.uminho.pt\/handle\/1822\/55615. Accessed 17 Apr 2025"},{"issue":"2","key":"4169_CR70","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2217\/nnm.10.1","volume":"5","author":"T Mamo","year":"2010","unstructured":"Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR et al (2010) Emerging nanotechnology approaches for HIV\/AIDS treatment and prevention. Nanomedicine 5(2):269\u2013285. https:\/\/doi.org\/10.2217\/nnm.10.1","journal-title":"Nanomedicine"},{"issue":"4","key":"4169_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/aac.02320-20.10.1128\/aac.02320-20","volume":"65","author":"S Mandal","year":"2021","unstructured":"Mandal S, Prathipati PK, Sunagawa SW, Destache CJ (2021) A concept evaluation study of a new combination bictegravir plus tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 preexposure prophylaxis. Antimicrob Agents Chemother 65(4):10\u20131128. https:\/\/doi.org\/10.1128\/aac.02320-20.10.1128\/aac.02320-20","journal-title":"Antimicrob Agents Chemother"},{"key":"4169_CR72","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2147\/IJN.S287310","volume":"16","author":"F Minooei","year":"2021","unstructured":"Minooei F, Fried JR, Fuqua JL, Palmer KE, Steinbach-Rankins JM (2021) In vitro study on synergistic interactions between free and encapsulated Q-griffithsin and antiretrovirals against HIV-1 infection. Int J Nanomed 16:1189\u20131206. https:\/\/doi.org\/10.2147\/IJN.S287310","journal-title":"Int J Nanomed"},{"issue":"2","key":"4169_CR73","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2174\/2210681207666170612084243","volume":"8","author":"D Mishra","year":"2018","unstructured":"Mishra D, Jindal AB (2018) Lipid based nanocarriers for delivery of anti-HIV drugs: a mini review. Nanosci Nanotechnol - Asia 8(2):172\u2013185. https:\/\/doi.org\/10.2174\/2210681207666170612084243","journal-title":"Nanosci Nanotechnol - Asia"},{"issue":"2","key":"4169_CR74","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0031-6997(24)01494-7","volume":"53","author":"SM Moghimi","year":"2001","unstructured":"Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53(2):283\u2013318. https:\/\/doi.org\/10.1016\/S0031-6997(24)01494-7","journal-title":"Pharmacol Rev"},{"issue":"8","key":"4169_CR75","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1080\/17425247.2021.1876660","volume":"18","author":"A Muheem","year":"2021","unstructured":"Muheem A, Baboota S, Ali J (2021) An in-depth analysis of novel combinatorial drug therapy via nanocarriers against HIV\/AIDS infection and their clinical perspectives: a systematic review. Expert Opin Drug Deliv 18(8):1025\u20131046. https:\/\/doi.org\/10.1080\/17425247.2021.1876660","journal-title":"Expert Opin Drug Deliv"},{"key":"4169_CR76","doi-asserted-by":"publisher","first-page":"105831","DOI":"10.1016\/j.jddst.2024.105831","volume":"98","author":"A Muheem","year":"2024","unstructured":"Muheem A, Waseem M, Sartaj A, Gaikwad S, More A, Iqubal A et al (2024a) d-\u03b1-tocopheryl polyethylene glycol succinate-decorated dual drug-loaded lipidic nanocarriers: a strategic approach for targeting lymphatic uptake and p-gp efflux modulation to enhance oral bioavailability in HIV-1 viral reservoirs. J Drug Deliv Sci Technol 98:105831. https:\/\/doi.org\/10.1016\/j.jddst.2024.105831","journal-title":"J Drug Deliv Sci Technol"},{"issue":"6","key":"4169_CR77","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1080\/02726351.2024.2320092","volume":"42","author":"A Muheem","year":"2024","unstructured":"Muheem A, Sartaj A, Aldosari E, Baboota S, Ali J (2024b) Enhancing lymphatic uptake of darunavir ethanolate through TPGS-enriched lipid nanocarriers for oral delivery. Part Sci Technol 42(6):988\u20131014. https:\/\/doi.org\/10.1080\/02726351.2024.2320092","journal-title":"Part Sci Technol"},{"issue":"1","key":"4169_CR78","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.antiviral.2009.07.016","volume":"85","author":"LK Naeger","year":"2010","unstructured":"Naeger LK, Struble KA, Murray JS, Birnkrant DB (2010) Running a tightrope: regulatory challenges in the development of antiretrovirals. Antiviral Res 85(1):232\u2013240. https:\/\/doi.org\/10.1016\/j.antiviral.2009.07.016","journal-title":"Antiviral Res"},{"issue":"Suppl 1","key":"4169_CR79","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4081\/idr.2013.s1.e6","volume":"5","author":"HM Naif","year":"2013","unstructured":"Naif HM (2013) Pathogenesis of HIV infection. Infect Dis Rep 5(Suppl 1):e6. https:\/\/doi.org\/10.4081\/idr.2013.s1.e6","journal-title":"Infect Dis Rep"},{"key":"4169_CR80","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jconrel.2021.05.003","volume":"334","author":"R Nunes","year":"2021","unstructured":"Nunes R, Bogas S, Faria MJ, Gon\u00e7alves H, L\u00facio M, Viseu T et al (2021) Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis. J Control Release 334:453\u2013462. https:\/\/doi.org\/10.1016\/j.jconrel.2021.05.003","journal-title":"J Control Release"},{"key":"4169_CR81","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.cbi.2023.110466","volume":"377","author":"AO Oladipo","year":"2023","unstructured":"Oladipo AO, Lebelo SL, Msagati TA (2023) Nanocarrier design\u2013function relationship: the prodigious role of properties in regulating biocompatibility for drug delivery applications. Chem Biol Interact 377:110466. https:\/\/doi.org\/10.1016\/j.cbi.2023.110466","journal-title":"Chem Biol Interact"},{"key":"4169_CR82","doi-asserted-by":"publisher","first-page":"1125577","DOI":"10.3389\/fpubh.2023.1125577","volume":"11","author":"W Oualikene-Gonin","year":"2023","unstructured":"Oualikene-Gonin W, Sautou V, Ezan E, Bastos H, Bellissant E, Belgod\u00e8re L et al (2023) Regulatory assessment of nano-enabled health products in public health interest. Position of the scientific advisory board of the French national agency for the safety of medicines and health products. Front Public Health 11:1125577. https:\/\/doi.org\/10.3389\/fpubh.2023.1125577","journal-title":"Front Public Health"},{"issue":"6","key":"4169_CR83","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","volume":"15","author":"R Paliwal","year":"2014","unstructured":"Paliwal R, Babu RJ, Palakurthi S (2014) Nanomedicine scale-up technologies: feasibilities and challenges. AAPS PharmSciTech 15(6):1527\u20131534. https:\/\/doi.org\/10.1208\/s12249-014-0177-9","journal-title":"AAPS PharmSciTech"},{"key":"4169_CR84","doi-asserted-by":"publisher","unstructured":"Pan J, Attia SA, Filipczak N, Torchilin VP (2020) Dendrimers for drug delivery purposes. Nanoengineered Biomaterials for Advanced Drug Delivery. Elsevier, pp 201\u201342. https:\/\/doi.org\/10.1016\/B978-0-08-102985-5.00010-3","DOI":"10.1016\/B978-0-08-102985-5.00010-3"},{"issue":"10","key":"4169_CR85","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/17425247.2019.1662786","volume":"16","author":"JL Paris","year":"2019","unstructured":"Paris JL, Baeza A, Vallet-Reg\u00ed M (2019) Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics. Expert Opin Drug Deliv 16(10):1095\u20131112. https:\/\/doi.org\/10.1080\/17425247.2019.1662786","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"4169_CR86","doi-asserted-by":"publisher","first-page":"e14805","DOI":"10.7759\/cureus.14805","volume":"13","author":"K Patel","year":"2021","unstructured":"Patel K, Zhang A, Zhang MH, Bunachita S, Baccouche BM, Hundal H et al (2021) Forty years since the epidemic: modern paradigms in HIV diagnosis and treatment. Cureus 13(5):e14805. https:\/\/doi.org\/10.7759\/cureus.14805","journal-title":"Cureus"},{"issue":"3","key":"4169_CR87","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3390\/pharmaceutics16030348","volume":"16","author":"MM Peet","year":"2024","unstructured":"Peet MM, Agrahari V, Clark MR, Doncel GF (2024) Preclinical and early clinical development of tenofovir alafenamide\/elvitegravir topical inserts for effective on-demand vaginal and rectal HIV prevention. Pharmaceutics 16(3):348. https:\/\/doi.org\/10.3390\/pharmaceutics16030348","journal-title":"Pharmaceutics"},{"issue":"12","key":"4169_CR88","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1016\/j.xphs.2018.07.032","volume":"107","author":"S Perazzolo","year":"2018","unstructured":"Perazzolo S, Shireman LM, Koehn J, McConnachie LA, Kraft JC, Shen DD et al (2018) Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman primates. J Pharm Sci 107(12):3153\u20133162. https:\/\/doi.org\/10.1016\/j.xphs.2018.07.032","journal-title":"J Pharm Sci"},{"issue":"3","key":"4169_CR89","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.xphs.2021.10.009","volume":"111","author":"S Perazzolo","year":"2022","unstructured":"Perazzolo S, Shen DD, Ho RJ (2022) Physiologically based pharmacokinetic modeling of 3 HIV drugs in combination and the role of lymphatic system after subcutaneous dosing. Part 2: Model for the drug-combination nanoparticles. J Pharm Sci 111(3):825\u2013837. https:\/\/doi.org\/10.1016\/j.xphs.2021.10.009","journal-title":"J Pharm Sci"},{"issue":"7","key":"4169_CR90","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","volume":"15","author":"JA Perez-Molina","year":"2015","unstructured":"Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Su\u00e1rez-Lozano I, Riera M et al (2015) Dual treatment with atazanavir\u2013ritonavir plus lamivudine versus triple treatment with atazanavir\u2013ritonavir plus two nucleos (t) ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. Lancet Infect Dis 15(7):775\u2013784. https:\/\/doi.org\/10.1016\/S1473-3099(15)00097-3","journal-title":"Lancet Infect Dis"},{"issue":"16","key":"4169_CR91","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2174\/0113892010275850240102105033","volume":"25","author":"RN Prajapati","year":"2024","unstructured":"Prajapati RN, Bhushan B, Singh K, Chopra H, Kumar S, Agrawal M et al (2024) Recent advances in pharmaceutical design: unleashing the potential of novel therapeutics. Curr Pharm Biotechnol 25(16):2060\u20132077. https:\/\/doi.org\/10.2174\/0113892010275850240102105033","journal-title":"Curr Pharm Biotechnol"},{"issue":"6","key":"4169_CR92","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","volume":"26","author":"A Puri","year":"2009","unstructured":"Puri A, Loomis K, Smith B, Lee J-H, Yavlovich A, Heldman E et al (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carr Syst 26(6):523\u2013580. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","journal-title":"Crit Rev Ther Drug Carr Syst"},{"key":"4169_CR93","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejpb.2014.11.021","volume":"89","author":"LN Ramana","year":"2015","unstructured":"Ramana LN, Sharma S, Sethuraman S, Ranga U, Krishnan UM (2015) Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs\u2013modern Trojan horses to combat HIV. Eur J Pharm Biopharm 89:300\u2013311. https:\/\/doi.org\/10.1016\/j.ejpb.2014.11.021","journal-title":"Eur J Pharm Biopharm"},{"key":"4169_CR94","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jconrel.2024.01.010","volume":"366","author":"IK Ram\u00f6ller","year":"2024","unstructured":"Ram\u00f6ller IK, Volpe-Zanutto F, Vora LK, Abbate MT, Hutton AR, McKenna PE et al (2024) Intradermal delivery of the antiretroviral drugs cabotegravir and rilpivirine by dissolving microarray patches: investigation of lymphatic uptake. J Control Release 366:548\u2013566. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.010","journal-title":"J Control Release"},{"key":"4169_CR95","unstructured":"Rodriguez Rela\u00f1o I (2022) Applications of polyanionic carbosilane dendrimers against HIV-1 and HCMV.\u00a0https:\/\/repositorio.uam.es\/bitstream\/handle\/10486\/700947\/rodriguez_relano_ignacio.pdf?sequence=1. Accessed 17 Apr 2025"},{"key":"4169_CR96","doi-asserted-by":"publisher","first-page":"120986","DOI":"10.1016\/j.ijpharm.2021.120986","volume":"607","author":"S Rojekar","year":"2021","unstructured":"Rojekar S, Pai R, Abadi LF, Mahajan K, Prajapati MK, Kulkarni S et al (2021) Dual loaded nanostructured lipid carrier of nano-selenium and etravirine as a potential anti-HIV therapy. Int J Pharm 607:120986. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120986","journal-title":"Int J Pharm"},{"issue":"6","key":"4169_CR97","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/diagnostics11061124","volume":"11","author":"EC Rosca","year":"2021","unstructured":"Rosca EC, Tadger P, Cornea A, Tudor R, Oancea C, Simu M (2021) International HIV dementia scale for HIV-associated neurocognitive disorders: a systematic review and meta-analysis. Diagnostics 11(6):1124. https:\/\/doi.org\/10.3390\/diagnostics11061124","journal-title":"Diagnostics"},{"key":"4169_CR98","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.imlet.2017.05.002","volume":"187","author":"H Rostami","year":"2017","unstructured":"Rostami H, Ebtekar M, Ardestani MS, Yazdi MH, Mahdavi M (2017) Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: a preliminary study. Immunol Lett 187:19\u201326. https:\/\/doi.org\/10.1016\/j.imlet.2017.05.002","journal-title":"Immunol Lett"},{"key":"4169_CR99","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.jpba.2017.05.006","volume":"147","author":"PK Sahu","year":"2018","unstructured":"Sahu PK, Ramisetti NR, Cecchi T, Swain S, Patro CS, Panda J (2018) An overview of experimental designs in HPLC method development and validation. J Pharm Biomed Anal 147:590\u2013611. https:\/\/doi.org\/10.1016\/j.jpba.2017.05.006","journal-title":"J Pharm Biomed Anal"},{"key":"4169_CR100","doi-asserted-by":"publisher","unstructured":"Sailaja I, Baghel MK, Shaker IA (2021) Nanotechnology based drug delivery for HIV-AIDS treatment. AIDS Updates-Recent Advances and New Perspectives: IntechOpen. https:\/\/doi.org\/10.5772\/intechopen.97736","DOI":"10.5772\/intechopen.97736"},{"key":"4169_CR101","doi-asserted-by":"publisher","first-page":"5248746","DOI":"10.1155\/2024\/5248746","volume":"2024","author":"S Sangeetha","year":"2024","unstructured":"Sangeetha S (2024) Formulation design, optimization, and evaluation of solid lipid nanoparticles loaded with an antiviral drug tenofovir using Box-Behnken design for boosting oral bioavailability. Adv Pharmacol Pharma Sci 2024:5248746. https:\/\/doi.org\/10.1155\/2024\/5248746","journal-title":"Adv Pharmacol Pharma Sci"},{"issue":"5","key":"4169_CR102","doi-asserted-by":"publisher","first-page":"506","DOI":"10.2174\/156720112802650707","volume":"9","author":"V Sankar","year":"2012","unstructured":"Sankar V, Nilaykumar Nareshkumar P, Nishit Ajitkumar G, Devi Penmetsa S, Hariharan S (2012) Comparative studies of lamivudine-zidovudine nanoparticles for the selective uptake by macrophages. Curr Drug Deliv 9(5):506\u2013514. https:\/\/doi.org\/10.2174\/156720112802650707","journal-title":"Curr Drug Deliv"},{"key":"4169_CR103","doi-asserted-by":"publisher","first-page":"232595822110090","DOI":"10.1177\/23259582211009011","volume":"20","author":"KK Scarsi","year":"2021","unstructured":"Scarsi KK, Swindells S (2021) The promise of improved adherence with long-acting antiretroviral therapy: what are the data? J Int Assoc Provid AIDS Care 20:23259582211009012. https:\/\/doi.org\/10.1177\/23259582211009011","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4\u20135","key":"4169_CR104","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.addr.2009.11.019","volume":"62","author":"P Sharma","year":"2010","unstructured":"Sharma P, Garg S (2010) Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62(4\u20135):491\u2013502. https:\/\/doi.org\/10.1016\/j.addr.2009.11.019","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"4169_CR105","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1021\/nl102184c","volume":"10","author":"J Shi","year":"2010","unstructured":"Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10(9):3223\u20133230. https:\/\/doi.org\/10.1021\/nl102184c","journal-title":"Nano Lett"},{"key":"4169_CR106","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fchem.2018.00360","volume":"6","author":"S Soares","year":"2018","unstructured":"Soares S, Sousa J, Pais A, Vitorino C (2018) Nanomedicine: principles, properties, and regulatory issues. Front Chem 6:360. https:\/\/doi.org\/10.3389\/fchem.2018.00360","journal-title":"Front Chem"},{"key":"4169_CR107","doi-asserted-by":"publisher","first-page":"112405","DOI":"10.1016\/j.colsurfb.2022.112405","volume":"213","author":"D Soundararajan","year":"2022","unstructured":"Soundararajan D, Ramana LN, Shankaran P, Krishnan UM (2022) Nanoparticle-based strategies to target HIV-infected cells. Colloids Surf, B 213:112405. https:\/\/doi.org\/10.1016\/j.colsurfb.2022.112405","journal-title":"Colloids Surf, B"},{"key":"4169_CR108","doi-asserted-by":"publisher","first-page":"112765","DOI":"10.1016\/j.jpba.2019.07.013","volume":"175","author":"DH Surve","year":"2019","unstructured":"Surve DH, Jindal AB (2019) Development and validation of reverse-phase high-performance liquid chromatographic (RP-HPLC) method for quantification of efavirenz in efavirenz-enfuvirtide co-loaded polymer-lipid hybrid nanoparticles. J Pharm Biomed Anal 175:112765. https:\/\/doi.org\/10.1016\/j.jpba.2019.07.013","journal-title":"J Pharm Biomed Anal"},{"issue":"10","key":"4169_CR109","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.1021\/acs.molpharmaceut.0c00773","volume":"17","author":"DH Surve","year":"2020","unstructured":"Surve DH, Jirwankar YB, Dighe VD, Jindal AB (2020) Long-acting efavirenz and HIV-1 fusion inhibitor peptide co-loaded polymer\u2013lipid hybrid nanoparticles: statistical optimization, cellular uptake, and in vivo biodistribution. Mol Pharm 17(10):3990\u20134003. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00773","journal-title":"Mol Pharm"},{"key":"4169_CR110","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2012.09.030","volume":"64","author":"S Svenson","year":"2012","unstructured":"Svenson S, Tomalia DA (2012) Dendrimers in biomedical applications\u2014reflections on the field. Adv Drug Deliv Rev 64:102\u2013115. https:\/\/doi.org\/10.1016\/j.addr.2012.09.030","journal-title":"Adv Drug Deliv Rev"},{"key":"4169_CR111","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11904-014-0207-y","volume":"11","author":"V Svicher","year":"2014","unstructured":"Svicher V, Ceccherini-Silberstein F, Antinori A, Aquaro S, Perno CF (2014) Understanding HIV compartments and reservoirs. Curr HIV\/AIDS Rep 11:186\u2013194. https:\/\/doi.org\/10.1007\/s11904-014-0207-y","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"4169_CR112","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/pharmaceutics13060904","volume":"13","author":"I Tanaudommongkon","year":"2021","unstructured":"Tanaudommongkon I, Tanaudommongkon A, Dong X (2021) Development of in situ self-assembly nanoparticles to encapsulate lopinavir and ritonavir for long-acting subcutaneous injection. Pharmaceutics 13(6):904. https:\/\/doi.org\/10.3390\/pharmaceutics13060904","journal-title":"Pharmaceutics"},{"key":"4169_CR113","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.2147\/IJN.S140569","volume":"12","author":"J Tang","year":"2017","unstructured":"Tang J, Jianming L, Guo L, Haitao Z, Ling W, Dai L et al (2017) Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis. Int J Nanomed 12:6687\u20136704. https:\/\/doi.org\/10.2147\/IJN.S140569","journal-title":"Int J Nanomed"},{"issue":"2","key":"4169_CR114","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jwip.12267","volume":"26","author":"B Tenni","year":"2023","unstructured":"Tenni B, Lexchin J, Phin S, Kittitrakul C, Gleeson D (2023) Lessons from India and Thailand for Cambodia\u2019s future implementation of the TRIPS Agreement for pharmaceutical patents. J World Intell Prop 26(2):166\u2013194. https:\/\/doi.org\/10.1111\/jwip.12267","journal-title":"J World Intell Prop"},{"key":"4169_CR115","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ijbiomac.2021.01.076","volume":"172","author":"DR Tompa","year":"2021","unstructured":"Tompa DR, Immanuel A, Srikanth S, Kadhirvel S (2021) Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. Int J Biol Macromol 172:524\u2013541. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.01.076","journal-title":"Int J Biol Macromol"},{"key":"4169_CR116","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.jddst.2021.102927","volume":"66","author":"MA Toscanini","year":"2021","unstructured":"Toscanini MA, Limeres MJ, Garrido AV, Cagel M, Bernabeu E, Moretton MA et al (2021) Polymeric micelles and nanomedicines: shaping the future of next generation therapeutic strategies for infectious diseases. J Drug Deliv Sci Technol 66:102927. https:\/\/doi.org\/10.1016\/j.jddst.2021.102927","journal-title":"J Drug Deliv Sci Technol"},{"key":"4169_CR117","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejps.2018.10.017","volume":"127","author":"P Walvekar","year":"2019","unstructured":"Walvekar P, Gannimani R, Govender T (2019) Combination drug therapy via nanocarriers against infectious diseases. Eur J Pharm Sci 127:121\u2013141. https:\/\/doi.org\/10.1016\/j.ejps.2018.10.017","journal-title":"Eur J Pharm Sci"},{"issue":"38","key":"4169_CR118","doi-asserted-by":"publisher","first-page":"2406143","DOI":"10.1002\/adma.202406143","volume":"36","author":"H Wang","year":"2024","unstructured":"Wang H, Li B, Sun Y, Ma Q, Feng Y, Jia Y et al (2024) NIR-II AIE luminogen-based erythrocyte-like nanoparticles with granuloma-targeting and self-oxygenation characteristics for combined phototherapy of tuberculosis. Adv Mater 36(38):2406143. https:\/\/doi.org\/10.1002\/adma.202406143","journal-title":"Adv Mater"},{"key":"4169_CR119","unstructured":"W.H. Organization (2021) WHO publishes new consolidated HIV guidelines for prevention, treatment, service delivery & monitoring 2021. Available from: https:\/\/www.who.int\/news\/item\/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring. Accessed 16 Apr 2025"},{"key":"4169_CR120","unstructured":"W.H. Organization (2024) HIV and AIDS 2024. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids. Accessed 16 Apr 2025"},{"issue":"6","key":"4169_CR121","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nmat2444","volume":"8","author":"KA Woodrow","year":"2009","unstructured":"Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Mark Saltzman W (2009) Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 8(6):526\u2013533. https:\/\/doi.org\/10.1038\/nmat2444","journal-title":"Nat Mater"},{"issue":"4","key":"4169_CR122","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/pharmaceutics11040184","volume":"11","author":"H Yang","year":"2019","unstructured":"Yang H, Li J, Patel SK, Palmer KE, Devlin B, Rohan LC (2019) Design of poly (lactic-co-glycolic acid)(PLGA) nanoparticles for vaginal co-delivery of griffithsin and dapivirine and their synergistic effect for HIV prophylaxis. Pharmaceutics 11(4):184. https:\/\/doi.org\/10.3390\/pharmaceutics11040184","journal-title":"Pharmaceutics"},{"issue":"9","key":"4169_CR123","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3390\/molecules25092193","volume":"25","author":"AA Yetisgin","year":"2020","unstructured":"Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O (2020) Therapeutic nanoparticles and their targeted delivery applications. Molecules 25(9):2193. https:\/\/doi.org\/10.3390\/molecules25092193","journal-title":"Molecules"},{"issue":"2","key":"4169_CR124","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41551-024-01208-4","volume":"9","author":"D Yin","year":"2025","unstructured":"Yin D, Zhong Y, Ling S, Lu S, Wang X, Jiang Z et al (2025) Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat Biomed Eng 9(2):185\u2013200. https:\/\/doi.org\/10.1038\/s41551-024-01208-4","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"4169_CR125","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu F, Chan J, Wang A, Langer R, Farokhzad O (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83(5):761\u2013769. https:\/\/doi.org\/10.1038\/sj.clpt.6100400","journal-title":"Clin Pharmacol Ther"},{"key":"4169_CR126","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.actbio.2024.11.024","volume":"191","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Zhu H, Xie K, Lu J, Chen X, Wang H (2025) A self-assembling cytotoxic nanotherapeutic strategy for high drug loading and synergistic delivery of molecularly targeted therapies. Acta Biomater 191:398\u2013411. https:\/\/doi.org\/10.1016\/j.actbio.2024.11.024","journal-title":"Acta Biomater"},{"issue":"14","key":"4169_CR127","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2217\/nnm.15.61","volume":"10","author":"J Zhao","year":"2015","unstructured":"Zhao J, Feng S-S (2015) Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine 10(14):2199\u20132228. https:\/\/doi.org\/10.2217\/nnm.15.61","journal-title":"Nanomedicine"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04169-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T04:12:17Z","timestamp":1759983137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04169-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":127,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04169-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}